Caspase-dependent and -independent suppression of apoptosis by monoHER in Doxorubicin treated cells

British Journal of Cancer

Volumn 96, Issue 3, 2007, Pages 450-456

  Bruynzeel, A M E ^a   Abou El Hassan, M A ^a,b   Torun, E ^a   Bast, A ^c   Van Der Vijgh, W J F ^a,c   Kruyt, F A E ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CAIRO UNIVERSITY   (Egypt)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

(non) tumour cells; Apoptosis; Caspases; Doxorubicin; MonoHER

Indexed keywords

7 MONOHYDROXYETHYLRUTOSIDE; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CASPASE 3; CASPASE 9; CASPASE INHIBITOR; DOXORUBICIN; PROTECTIVE AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOACCUMULATION; CANCER CELL; CANCER CELL DESTRUCTION; CANCER RESISTANCE; CARDIOTOXICITY; CELL DEATH; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME DEGRADATION; ENZYME MECHANISM; FEMALE; HEART MUSCLE CELL; HEART PROTECTION; HUMAN; HUMAN CELL; MITOCHONDRION; MOLECULAR BIOLOGY; NEWBORN; NONHUMAN; OVARY CANCER; OVARY CELL; PRIORITY JOURNAL; RAT;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CASPASES; CELL CYCLE; CELL LINE; CYTOPROTECTION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; ENDOTHELIAL CELLS; ENZYME ACTIVATION; FLAVONOIDS; HUMANS; MYOCYTES, CARDIAC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33846816973     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603598     Document Type: Article

References (42)

1. Abou El Hassan MAI, Heijn M, Rabelink MJWE, van der Vijgh WJ, Bast A, Hoeben RC (2003a) The protective effect of cardiac gene transfer of CuZn-sod in comparison with the cardioprotector monohydroxyethyl-rutoside against doxorubicin-induced cardiotoxicity in cultured cells. Cancer Gene Ther 10: 270-277
2. Abou El Hassan MAI, Kedde MA, Zwiers UTH, Bast A, van der Vijgh WJF (2003b) The cardioprotector monoHER does not interfere with the pharmacokinetics or the metabolism of the cardiotoxic agent doxorubicin in mice. Cancer Chemother Pharmacol 51: 306-310
3. Abou El Hassan MAI, Kedde MA, Zwiers UTH, Torun E, Haenen GRMM, Bast A, van der Vijgh WJF (2003c) Bioavailability and pharmacokinetics of the cardioprotecting flavonoid monohydroxyethylrutoside in mice. Cancer Chemother Pharmacol 52: 371-376
4. Abou El Hassan MAI, Verheul HMW, Jorna AS, Schalkwijk C, van Bezu J, van der Vijgh WJF, Bast A (2003d) The new cardioprotector Monohydroxyethylrutoside protects against doxorubicin-induced inflammatory effects in vitro. Br J Cancer 89: 357-362
5. Binaschi M, Capranico G, Dal Bo L, Zunino F (1997) Relationship betweenlethal effects and topoisomerase II-mediated double-stranded DNA breaks produced by anthracyclines with different sequence specificity. Mol Pharmacol 51: 1053-1059
6. Bröker LE, Kruyt FAE, Giaccone G (2005) Cell death independent of caspases: a review. Clin Cancer Res 11: 3155-3162
7. Camarda G, Binaschi M, Maggi CA, Goso C (2002) Nuclear factor-κB, induced in human carcinoma cell line A2780 by the new anthracycline MEN 10755, is devoid of transcriptional activity. Int J Cancer 102: 476-482
8. Capranico G, Kohn KW, Pommier Y (1990) Local sequence requirements for DNA cleavage by mammalian topoisomerase II in the presence of doxorubicin. Nucleic Acids Res 18: 6611-6619
9. Childs AC, Phaneuf SL, Dirks AJ, Phillips T, Leeuwenburgh C (2002) Doxorubicin treatment in vivo causes cytochrome C release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2: Bax ratio. Cancer Res 62: 4592-4598
10. Gewirtz DA (1991) Does bulk damage to DNA explain the cytostatic and cytotoxic effects of topoisomerase II inhibitors? Biochem Pharmacol 42: 2253-2258
11. Gerwitz DA (1999) A critical evaluation of the mechanism of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57: 727-741
12. Gouaze V, Mirault ME, Carpentier S, Salvayre R, Levade T, Andrieu-Abadie N (2001) Glutathione peroxidase-1 overexpression prevents ceramide production and partially inhibits apoptosis in doxorubicin-treated human breast carcinoma cells. Mol Pharmacol 60: 488-496
13. Grassilli E, Ballabeni A, Maellaro E, Del Bello B, Helin K (2004) Loss of MYC confers resistance to doxorubicin-induced apoptosis by preventing the activation of multiple serine protease- and caspase-mediated pathways. J of Biol Chem 279: 21318-21326
14. Haddad JJ (2004) Hypoxia and the regulation of mitogen-activated protein kinases: gene transcription and the assessment of potential pharmacologic therapeutic interventions. Int Immunopharmacol 4: 1249-1285
15. Haenen GRMM, Jansen FP, Bast A (1993) The antioxidant properties of five O- (beta-hydroxyethyl) rutosides of the flavonoid mixture Venoruton. Phlebology 1(Suppl): 10-17
16. Horenstein MS, Vander Heide RS, L'Ecuyer TJ (2000) Molecular basis of anthracycline-induced cardiotoxicity and its prevention. Mol Gen and Metabol 71: 436-444
17. Hrdina R, Gersl V, Klimtova I, Simunek T, Machackova J, Adamcova M (2000) Anthracycline-induced cardiotoxicity. Acta Medica 43: 75-82
18. Kalivendi S, Konorev EA, Cunningham S, Vanamala SK, Kaji EH, Joseph J, Kalyanaraman B (2005) Doxorubicin activates nuclear factor of activated T-lymfocytes and Fas ligand transcription: role of mitochondrial reactive oxygen species and calcium. Biochem J 389: 527-539
19. Keizer HG, Pinedo HM, Schuurhuis GJ, Joenje H (1991) Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity. Pharmacol Ther 47: 219-231
20. Kluza J, Marchetti P, Gallego MA, Lancel S, Fournier C, Loyens A, Beauvillain JC, Bailly C (2004) Mitochondrial proliferation during apoptosis induced by anticancer agents: effects of doxorubicin and mitoxantrone on cancer and cardiac cells. Oncogene 23: 7018-7030
21. Kotamraju S, Konorev EA, Joseph J, Kalyanaraman B (2000) Doxorubicin-induced apoptosis in endothelial cells and cardiomyocytes is ameliorated by nitrone spin traps and ebselen. Role of reactive oxygen and nitrogen species. J Biol Chem 275: 33585-33592
22. Krause MS, Oliveira Jr LP, Silveira EMS, Vianna DR, Rossato JS, Almeida BS, Rodrigues MF, Fernandes AJM, Costa JAB, Curi R, Homem de Bittencourt Jr PI (2007) MRP1-GS-X pump ATPase expression: is this the explanation for the cytoprotection of the heart against oxidative stress-induced redox imbalance in comparison to skeletal muscle cells? Cell Biochem Funct 25: 23-32
23. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA (1973) A Clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 32: 302-314
24. Liu X, Chen Z, Chua CC, Ma YS, Youngberg GA, Hamdy R, Chua BHL (2002) Melatonin as an effective protector against doxorubicin-induced cardiotoxicity. Am J Physiol Heart Circ Physiol 283: H254-H263
25. Maciag T, Cerundolo J, Ilsely S, Kelley PR, Forand R (1979) An endothelial cell growth factor from bovine hypothalamus: identification and partial characterization. Proc Natl Acad Sci USA 76: 5674-5678
26. Nakamura T, Ueda Y, Juan Y, Katsuda S, Takahashi H, Koh E (2000) Fas-mediated apoptosis in adriamycin-induced cardiomyopathy in rats. Circulation 102: 572-578
27. Oliveira PJ, Bjork JA, Santos MS, Leino RL, Froberg MK, Moreno AJ, Wallance KB (2004) Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity. Toxicol Appl Pharmacol 200: 159-168
28. Shacter E, Williams JA, Hinson RM, Senturker S, Lee YJ (2000) Oxidative stress interferes with cancer chemotherapy: inhibition of lymphoma cell apoptosis and phagocytosis. Blood 96: 307-313
29. Singal PK, Iliskovic N (1998) Doxorubicin-induced cardiomyopathy. N Eng J Med 339: 900-904
30. Spallarossa P, Garibaldi S, Altieri P, Fabbi P, Manca V, Nasti S, Rossettin P, Ghigliotti G, Ballestrero A, Patrone F, Barsotti A, Brunelli C (2004) Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro. J Mol Cell Cardiol 37: 837-846
31. Suresh A, Guedez L, Moreb J, Zucali J (2003) Overexpression of manganese superoxide dismutase promotes survival in cell lines after doxorubicin treatment. Br J Haematol 120: 457-463
32. Swain SM, Whaley FS, Gerber MC, Weisberg S, York M, Spicer D, Jones SE, Wadler S, Desai A, Vogel C, Speyer J, Mittelman A, Reddy S, Pendergrass K, Velez-Garcia E, Ewer MS, Bianchine JR, Gams RA (1997) Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 15: 1318-1322
33. Uberti D, Yavin E, Gil S, Ayasola KR, Goldfinger N, Rotter V (1999) Hydrogen peroxide induced nuclear translocation of p53 and apoptosis in cells of oligodendroglia origin. Brain Res Mol Brain Res 65: 167-175
34. van Acker FA, van Acker SABE, Kramer K, Haenen GRMM, Bast A, van der Vijgh WJ (2000) 7-Monohydroxyethylrutoside protects against chronic doxorubicin-induced cardiotoxicity when administered only once per week. Clin Cancer Res 6: 1337-1341
35. van Acker SABE, Boven E, Kuiper K, van den Berg DJ, Grimbergen JA, Kramer K, Bast A, van der Vijgh WJ (1997) Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin. Clin Cancer Res 3: 1747-1754
36. van Acker SABE, Towart R, Husken BCP, de Jong J, van der Vijgh WJF, Bast A (1993) The protective effect of Venoruton and its constituents on acute doxorubicin-induced cardiotoxicity. Phlebology Suppl 1: 31-32
37. Verheul HMW, Jorna AS, Hoekman K, Broxterman HJ, Gebbink MFBG, Pinedo HM (2000) Vascular endothelial growth factor-stimulated endothelial cells promote adhesion and activation of platelets. Blood 96: 4216-4221
38. Willems AM, Bruynzeel AME, Kedde MA, van Groeningen CJ, Bast A, van der Vijgh WJF (2006) A phase 1 study of monohydroxyethylrutoside in healthy volunteers. Cancer Chemother Pharmacol 57: 678-684
39. Wu S, Ko YS, Teng MS, Ko YL, Hsu LA, Hsueh C, Chou YY, Liew CC, Lee YS (2002) Adriamycin-induced cardiomyocyte and endothelial cell apoptosis: in vitro and in vivo studies. J Mol Cell Cardiol 34: 1595-1607
40. Xu MF, Tang PL, Oian ZM, Ashraf M (2001) Effects by doxorubicin on the myocardium are mediated by oxygen free radicals. Life Sci 68: 889-901
41. Yamanaka S, Tatsumi T, Shiraishi J, Mano A, Keira N, Matoba S, Asayama J, Fushiki S, Fliss H, Nakagawa M (2003) Amlodipine inhibits doxorubicin-induced apoptosis in neonatal rat cardiac myocytes. J Am Cell Cardiol 41: 870-878
42. Youn HJ, Kim HS, Jeon MH, Lee JH, Seo YL, Lee YJ, Lee JH (2005) Induction of caspase-independent apoptosis in H9c2 cardiomyocytes by adriamycin treatment. Mol Cell Biochem 270: 13-19